Download the Protocol

Tirzepatide

Tirzepatide is a once-weekly injectable compound that helps regulate blood sugar and appetite. It combines two natural hormone signals to support weight loss and better energy balance, making it one of the most effective options for managing obesity and metabolic issues.

Description

• Tirzepatide (Mounjaro® / Zepbound®) is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly.
• Designed to improve insulin sensitivity, suppress appetite, and enhance metabolic efficiency.
• Approved for type 2 diabetes and obesity management due to significant effects on blood sugar and fat reduction.

How It Works

• Activates both GLP-1 and GIP receptors, enhancing insulin secretion and improving glucose control.
• Reduces appetite and delays gastric emptying to decrease food intake.
• Stimulates energy expenditure and fat oxidation, leading to weight reduction.

Documented Effects

• Clinical trials show 15–22% average body-weight loss at high doses over 72 weeks.
• Improves HbA1c, triglycerides, and liver fat content.
• Common side effects include transient nausea, mild constipation, or reduced appetite.

Theoretical Effects

• May offer enhanced weight-loss synergy compared to GLP-1 monotherapy (e.g., semaglutide).
• Potential applications in metabolic syndrome, fatty liver disease, and insulin resistance research.
• Long-term cardiometabolic benefits remain under study.

Pharmacokinetics

• Half-life: approximately 120 hours (~5 days), allowing once-weekly dosing.
• Time to peak concentration: 1–2 days post-injection.
• Steady-state levels: reached after 4–5 weeks of continuous use.

Duration of Effects

• Appetite suppression and glucose-lowering effects last about 7 days per injection.
• Weight-management benefits accumulate over several months of therapy.
• Residual effects may persist 2–3 weeks after discontinuation due to slow clearance.

Reconstitution

• Use only bacteriostatic water to mix the lyophilized powder.
• Example vial: 10 mg of Tirzepatide
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; avoid shaking.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (First-Time Use)

Typical Starting Dose

• Injectable (clinical use): 2.5 mg subcutaneous (SC) once weekly.
• Gradual escalation recommended: increase by 2.5 mg every 4 weeks as tolerated.

Common Therapeutic Range

• Effective range: 5–15 mg SC once weekly.
• Higher doses (10–15 mg) associated with greater fat loss but more GI discomfort.

Maximum Weekly Dose

• Maximum approved dose: 15 mg once weekly.
• Higher experimental doses not supported by long-term safety data.

Standard Cycle Length

• Used as a long-term therapy (≥ 12 months) for sustained metabolic improvement.
• Discontinuation typically results in gradual weight regain unless lifestyle changes maintained.

Clinical Notes

• Inject subcutaneously in the abdomen, thigh, or upper arm; rotate injection sites weekly.
• Taper dosing when discontinuing to avoid rapid appetite rebound.
• Avoid combining with other incretin-based peptides (GLP-1 or GIP agonists).
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Begin with 2.5 mg to minimize nausea, bloating, or constipation.
• Avoid stacking with other GLP-1 receptor agonists or incretin-based compounds.
• Contraindicated in individuals with MEN2 or a family history of medullary thyroid carcinoma.
• Monitor hydration and protein intake during caloric restriction.
• Long-term cardiovascular outcome data are positive and ongoing.